Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 27;22(1):8.
doi: 10.1007/s11912-020-0872-5.

Low-grade Serous Tumors: Are We Making Progress?

Nina Pauly  1 , Sarah Ehmann  1 , Enzo Ricciardi  1 , Beyhan Ataseven  1   2 , Mareike Bommert  1 , Florian Heitz  1 , Sonia Prader  1 , Stephanie Schneider  1 , Andreas du Bois  1 , Philipp Harter  1 , Thaïs Baert  3   4
Affiliations
Review

Low-grade Serous Tumors: Are We Making Progress?

Nina Pauly et al. Curr Oncol Rep. .

Abstract

Purpose of review: This review provides an overview of the current clinical standard in low-grade serous ovarian cancer (LGSOC). The available evidence for surgery and standard treatments is elaborated. In addition, we discuss recent findings and novel treatments for LGSOC.

Recent findings: Two large multicenter trials studying MEK inhibitors in LGSOC have been presented in the last year. Binimetinib demonstrated an activity in LGSOC, especially in KRAS-mutated disease. Trametinib was associated with an improved progression-free survival in relapsed LGSOC. Based on the current results, MEK inhibitors could be an alternative treatment for LGSOC. Surgery is an important step in the treatment of LGSOC. Hormonal therapy and bevacizumab can be beneficial, next to chemotherapy. Targeted treatments, such as the MEK-inhibitor trametinib, seem to be efficient and should be introduced into clinical practice.

Keywords: Low-grade serous - rare tumor; MEK inhibitor; Ovarian cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ann Oncol. 2019 May 1;30(5):672-705 - PubMed
    1. Gynecol Oncol. 2012 Jun;125(3):661-6 - PubMed
    1. Obstet Gynecol. 2002 Jan;99(1):3-10 - PubMed
    1. Am J Surg Pathol. 2004 Apr;28(4):496-504 - PubMed
    1. J Clin Oncol. 2015 Dec 1;33(34):4099-105 - PubMed

MeSH terms

Substances

LinkOut - more resources